Key Takeaways Madrigal posted a Q3 loss of $5.08 per share, wider than the expected $1.98 loss.Rezdiffra sales hit $287.3M, surpassing estimates and fueling strong investor response.EU approval and new licensing moves reinforce Madrigal's expanding MASH franchise.Madrigal Pharmaceuticals (MDGL) reported third-quarter 2025 loss of $5.08 per share, wider than the Zacks Consensus Estimate of a loss of $1.98. In the year-ago quarter, the company had incurred a loss of $4.92 per share.During the quarter, the com ...